Lincoln Pharmaceuticals

Lincoln Pharma delivered a solid Q3 FY26 with revenue of ₹166.3 CrCurrent reported value: ₹166.3 Cr. No comparable prior figure is available in the source record. (+13.5Current reported value: 13.5. No comparable prior figure is available in the source record.% YoY) and PAT of ₹28.6 CrCurrent reported value: ₹28.6 Cr. No comparable prior figure is available in the source record. (+37.7Current reported value: 37.7. No comparable prior figure is available in the source record.% YoY), driven by strong export growth and the new cephalosporin (CIFA) block contributing ~₹45 CrCurrent ₹45 Cr. Reported change: New. annualized. EBITDA margin expanded ~100 bps to 23.3%Current reported value: 23.3%. No comparable prior figure is available in the source record., aided by favorable product mix and operating leverage. Management reiterated the ₹1,000 Cr revenue targetCurrent reported value: ₹1,000 Cr revenue target. No comparable prior figure is available in the source record. (likely by FY28-29Current reported value: 29. No comparable prior figure is available in the source record.) with growth from domestic branded generics, regulated markets (Canada, EU), and potential inorganic acquisitions. R&D spend is set to rise from ~2% to ~3% of sales to support dossier filings. Key risk: EU re-inspection delays could push back regulated market revenue ramp-up.